Immunome Q2 net loss $73.1M; FDA accepts varegacestat NDA, PDUFA April 28, 2027

Immunome Inc.

FDA accepted NDA for varegacestat in desmoid tumors; PDUFA target April 28, 2027.
Phase 3 RINGSIDE: 84% risk reduction (HR=0.16, p<0.0001); ORR 56% vs 9%.
Cash $520.0M as of June 30, 2026; expected to fund operations into 2028.
Q2 net loss $73.1M; R&D $59.9M, G&A $18.3M including stock comp.
First patients dosed in Phase 1 trials of IM-1617 (June 2026) and IM-3050 (July 2026).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.